

RESEARCH RETREAT Agenda* DAY 1

	11
Q	ER
N	
5	00

	THEME	TALK	TIME	TOPIC	SPEAKER			
			10:45 AM ET	Welcome & Opening Remarks	Bruce Roberts, PhD			
SESSION 1	Keynote	1.1	11:00 AM ET	Peanut Allergy Prevention Guidelines Are Not Working: Lessons From LEAP and EAT	Gideon Lack, MD			
		1.2	11:20 AM ET	The Genetics of Peanut Allergy: Lessons from the LEAP Study	Rasika Mathias, ScD			
		1.3	11:40 AM ET	Basophil and Mast Cell Activation as Biomarkers of Food Allergy and Oral Tolerance	Alexandra Santos MD, PhD			
		1.4	12:00 PM ET	Live Par	el Discussion			
BREAK								
ESSION 2	Disease Development	2.1	1:00 PM ET	Microbiome Modulating Therapeutics for Food Allergy	Cathryn Nagler, PhD			
		2.2	1:25 PM ET	Enteric Neurons and the Control of Appetite	Ivan de Araujo, PhD			
		2.3	1:50 PM ET	Maternal Regulation of Neonatal Food Tolerance	Michiko Oyoshi, PhD, MSc			
		2.4	2:15 PM ET	Live Panel Discussion				
BREAK								
SESSION 3	Patient Data	3.1	3:30 PM ET	FARE Patient Data: Improving Upon and Expanding Beyond Patient Reported Outcomes (PROs)	Jennifer Bufford, MS			
		3.2	3:55 PM ET	Clinical Profiles of Patients With Food Allergy From the FARE Patient Registry	Sachin Gupta, MD			
		3.3	4:20 PM ET	Food Allergy Characteristics Associated With Co-existing Eosinophilic Esophagitis in Food Allergy Research & Education (FARE) Patient Registry Participants	Katharine Guarnieri, MD			
		3.4	4:45 PM ET	Multi-institutional Food Challenge Data Set	Jonathan Spergel, MD, PhD			
		3.5	5:10 PM ET	Live Panel Discussion				
	BREAK							
SESSION 4	Keynote	4.1	6:00 PM ET	Progress Highlights Over the Last Year with a Focus on Diagnostics and Prevention	Kari Nadeau, MD, PhD			
		4.2	6:30 PM ET	Live Panel Discussion				
				I				

*Agenda as of October 7, 2022. Please note, agenda is subject to change.

FARE is pleased to welcome guests and speakers with a wide range of expertise and a variety of perspectives. It is possible some views expressed may not reflect those of FARE. However, we welcome insights from all and look forward to an exciting exchange of information and robust conversation. Copying of any Research Retreat presentations is strictly forbidden.



RESEARCH RETREAT Agenda* DAY 2

WEDNESDAY OCTOBER 12

	THEME	TALK	TIME	ТОРІС	SPEAKER			
			10:45 AM ET	Welcome & Opening Remarks	Bruce Roberts, PhD			
SESSION 5	Diagnosis	5.1	11:00 AM ET	Streamlining and Democratizing Flow Cytometry Based Basophil Activation Testing	Jean-Marc Busnel, PhD			
		5.2	11:25 AM ET	Allergen Thresholds: Improving the Management of Food- allergic Individuals	Paul Turner, PhD			
		5.3	11:50 AM ET	B Cell Receptor Repertoire in Allergic Dermatitis Supports Altered IgE Maturation Associated With Atopic Severity	Krishna Roskin, PhD			
		5.4	12:15 PM ET	Inflammatory Responses of the Esophageal Mucosa to Ex Vivo Food Challenge in Adults With Eosinophilic Esophagitis	Mirelle Kleuskens, MSc			
		5.5	12:30 PM ET	Live Panel Discussion	ion			
1:00 PM ET - Diversity Scholars Infomercial								
ESSION 6	Treatments	6.1	1:30 PM ET	ZENITH: Efficacy of Tezepelumab in Peanut Oral Immunotherapy	Edwin Kim, MD, MS Michelle Huffaker, MD			
		6.2	1:55 PM ET	Siglec-2 Targeted Approaches to Prevent and Treat Peanut Allergy	Michael Kulis, PhD			
		6.3	2:20 PM ET	Dupilumab (Dupixent) for the Treatment of Eosinophilic Esophagitis	Jennifer Maloney, MD			
		6.4	2:45 PM ET	Live Panel Discussion				
				BREAK				
SESSION 7	Prevention and Remission	7.1	3:30 PM ET	Childhood Activities Nutrition and Development Oversight (CAN DO) Study	Ruchi Gupta, MD, MPH			
		7.2	3:55 PM ET	Nutrition and Food Allergy Prevention	Helen A Brough, MBBS, MA, MSc, PhD			
		7.3	4:20 PM ET	Maternal Diet and Allergy Outcomes	Carina Venter, PhD, RD			
		7.4	4:45 PM ET	Achieving Remission of Food Allergy With Oral Immunotherapy	Mimi Tang, MBBS, PhD			
		7.5	5:10 PM ET	Live Panel Discussion				
BREAK								
SESSION 8	Keynote	8.1	6:00 PM ET	NIH Funded Studies Introduction	Alkis Togias, MD			
		8.2	6:10 PM ET	SUNBEAM: Systems Biology of Early Atopy	Corinne Keet, MD, PhD			
		8.3	6:30 PM ET	iREACH: Intervention to Reduce Early (Peanut) Allergy in Children	Ruchi Gupta, MD, MPH Lucy Bilaver, PhD			
		8.4	6:50 PM ET	The ACTIVATE Pilot Study: Exposure to Vaginal Microbiome in C-section Infants at High-risk for Allergies	Jose Clemente, PhD			
		8.5	7:10 PM ET	Live Panel Discussion	Dn			

This concludes the 2022 Contains: Courage Research Retreat. Thank you for joining us!

*Agenda as of October 7, 2022. Please note, agenda is subject to change.

FARE is pleased to welcome guests and speakers with a wide range of expertise and a variety of perspectives. It is possible some views expressed may not reflect those of FARE. However, we welcome insights from all and look forward to an exciting exchange of information and robust conversation. Copying of any Research Retreat presentations is strictly forbidden.



RESEARCH RETREAT Speaker BIOGRAPHIES



Ivan de Araujo, PhD

Icahn School of Medicine at Mount Sinai Ivan de Araujo is a professor in the department of neuroscience at the Icahn School of Medicine at Mount Sinai. His research focuses on identifying and characterizing the large scale neural networks that link the body to the brain, with an emphasis on the gut-brain axis. One goal of his research is to understand allergen-sensing pathways in the gut, and how these signals access the central nervous system.

Dr. de Araujo majored in Philosophy at the University of Brasilia, followed by postgraduate work in Artificial Intelligence at the University of Edinburgh. He obtained his Doctorate (DPhil) in Medical Physiology and Imaging at the University of Oxford.



Lucy Bilaver, PhD Northwestern University Feinberg School of Medicine Dr. Bilaver is an applied health services researcher with expertise using administrative data for research purposes. She focuses on timely issues in pediatric health services research that have policy implications. Dr. Bilaver earned a PhD from the University of Chicago's Crown Family School of Social Work, Policy, and Practice and an MS in statistics. She completed her post-doctoral training in health services research through an Integrated Fellowship at Feinberg. As an associate professor of pediatrics at Northwestern Medicine, her child health services research program spans several areas of children with special health care needs including food allergy, autism, asthma, and obesity.

She is the lead statistician and co-investigator for the Intervention to Reduce Early (Peanut) Allergy in Children (iREACH) study (NIH U01Al138907), a pragmatic clinical trial to test the effectiveness of clinician education and clinical decision support to increase pediatric clinician adherence to the NIAID Addendum peanut allergy prevention guideline and to decrease the incidence of peanut allergy. In addition, she is the Principal Investigator for a study (NIH R21 Al159562) that leverages private and public medical claims data to examine the role of social, economic and environmental factors in food allergy disparities.



Helen A Brough, MBBS, MA, MSc, PhD

Evelina London, Guy's and St. Thomas' NHS Foundation Trust Dr. Brough is a Consultant in Pediatric Allergy, and Head of Service for the largest Children's Allergy Service in the UK at the Evelina London Children's Hospital, Guy's and St. Thomas' NHS Foundation Trust.

Helen is an Adjunct Reader at King's College London University. Her research interests are in genetic and environmental risk factors for the development of food allergy, cutaneous sensitization and the prevention, diagnosis and management of food allergy and severe asthma. She is a multi-PI for the multicenter Stopping Eczema and Allergy (SEAL) study (NIH U01AI147462), evaluating whether proactive skin care in young infants with dry skin or eczema will prevent the development of food allergy. She led the UK arm of the Pronuts study, evaluating the rate of challenge-proven peanut, tree nut and sesame seed allergy in the UK, Spain and Geneva. She was involved in the Learning Early About Peanut allergy (LEAP), LEAP-On and Enquiring About Tolerance (EAT) studies that have resulted in a paradigm shift in the way food allergies are prevented.

Dr. Brough is the past Chair of the Pediatric Section for the European Academy of Allergy and Clinical Immunology (EAACI 2019-2022). She is the President of the Royal Society of Medicine Allergy and Immunology Section. She was awarded the 2020 Distinguished Clinician Award by the American Academy of Asthma, Allergy and Immunology (AAAAI).

Dr. Brough read Medicine at King's College, Cambridge University before completing her clinical training at the Royal Free & University College London Medical School. She completed her MSc at the University of Southampton and her PhD at King's College London.



Jennifer Bufford, MS

As Vice President of Clinical Operations, Jennifer is responsible for executing FARE's research operations and advancing the science and technology of food allergy. Prior to joining FARE, she spent nearly two decades in academic medicine, creating and enhancing pathways for faculty to successfully engage in investigator-initiated clinical research. She brings expertise in the management of research consortia and the implementation of multisite clinical trials. Jennifer has a bachelor's degree in medical microbiology and immunology and a master's degree in biotechnology, both from the University of Wisconsin-Madison.



Jean-Marc Busnel, PhD Beckman Coulter Life Sciences During his PhD at the ESPCI in Paris, France, and a postdoctoral fellowship at the EPFL in Lausanne, Switzerland, Jean-Marc Busnel was able to conduct various research projects in the broader field of bioanalytics. Focusing on capillary electrophoresis, microfluidics and mass spectrometry and to their application in the fields of metabolomics and proteomics, the overall intent was to push achievable limits in terms of speed, sensitivity and overall applicability. He then joined Beckman Coulter Life Sciences to lead the further development of sheathless capillary electrophoresis electrospray ionization mass spectrometry, a technology now commercialized by Sciex. Now, leading a research team dedicated to translational research, Jean-Marc Busnel works on further leveraging the capabilities of flow cytometry for biologics characterization and patient stratification in various pathological areas such as allergy, autoimmunity, infectious diseases and oncology.



Jose Clemente, PhD Icahn School of Medicine at Mount Sinai

Dr. Clemente is currently an Associate Professor in the Department of Genetics and Genomic Sciences and the Immunology Institute at the Icahn School of Medicine at Mount Sinai. Prior to joining Mount Sinai in 2013, he received his BSc from University of Seville (Spain), and his MSc and PhD from the Japan Advanced Institute of Science and Technology (Japan). He completed his postdoctoral training at the National Institute of Genetics (Japan) and at the University of Colorado. He has over 15 years of expertise in the microbiome, a field in which he has published more than 100 articles that have received over 60,000 citations. His lab develops computational and experimental methods to understand the microbiome in relation to immune disorders, including allergies.



Katharine Guarnieri, MD Cincinnati Children's Hospital Medical Center

Dr. Guarnieri recently completed Allergy and Immunology fellowships at Cincinnati Children's Hospital Medical Center where she pursued a two-year clinical fellowship followed by a one-year advanced research fellowship. Dr. Guarnieri's research has been focused in three primary areas – oral immunotherapy, including co-creation of an egg oral immunotherapy protocol for Cincinnati Children's Division of Allergy and Immunology; amoxicillin-associated reactions presenting to the acute care setting, which contributed to the development of the division's Penicillin Allergy Testing Service; and, most recently, food allergy in those with co-existing eosinophilic esophagitis utilizing the FARE Patient Registry.

Dr. Guarnieri was a member of the National Scholars Program at Clemson University where she received a Bachelor of Science in health science and minor in business administration. She earned her medical degree from the University of Cincinnati College of Medicine and was inducted into the Alpha Omega Alpha Honor Medical Society in her third year. She then completed her pediatric residency at Cincinnati Children's Hospital Medical Center.



Ruchi Gupta, MD, MPH Northwestern University Feinberg

Northwestern University Feinberg School of Medicine Dr. Gupta is a Professor of Pediatrics and Medicine at Northwestern University Feinberg School of Medicine and has more than 17 years of experience as a boardcertified pediatrician and health researcher. Dr. Gupta is the director of the Center for Food Allergy & Asthma Research (CFAAR) within Northwestern's Institute for Public Health and Medicine and is a clinical attending at Ann & Robert H. Lurie Children's Hospital Chicago, where she is actively involved in clinical, epidemiological, and community-based research. She is nationally recognized for her groundbreaking research in the areas of food allergy and asthma epidemiology, specifically, her research on childhood food allergy prevalence. She has also significantly contributed to academic research surrounding economic costs, pediatric management of food allergy and asthma, ED visits and hospitalizations, quality of life and community interventions, especially in schools. Along with being an author of The Food Allergy Experience and Food Without Fear, Dr. Gupta has over 160 publications, and her work has been featured in major TV networks and print media.



Michelle Huffaker, MD

Immune Tolerance Network

Dr. Gupta is a Pulmonary & Critical Care physician whose interest in clinical research led him to join the Genentech team in 2020. Since joining, he has supported the food allergy development team to understand the unmet research and education needs in food allergy and work with researchers worldwide to help address those knowledge gaps.

Dr. Michelle Huffaker is the Director of Clinical Translational Medicine for the Allergy Portfolio at the Immune Tolerance Network. Her work focuses on allergy clinical trial development, conduct, and analysis. She serves as the Clinical Trial Physician for several Immune Tolerance Network trials, including LEAP Trio, the follow–up study of LEAP participants and their families, and GRADUATE, a trial of dupilumab and sublingual grass immunotherapy.

After earning her undergraduate degree from Princeton University and medical degree from Harvard Medical School, Dr. Huffaker completed Internal Medicine residency at the Brigham and Women's Hospital in Boston. She completed fellowship in Adult and Pediatric Allergy/Immunology at Stanford University. Dr. Huffaker joined the Allergy and Asthma Medical Group of the Bay Area in 2017, and the Immune Tolerance Network in 2020.



Corinne Keet, MD, PhD University of North Carolina at Chapel Hill Dr. Keet is currently a Professor of Pediatrics and board-certified allergist. She is active in conducting clinical, epidemiological and translational research into the prevention and treatment of food allergies.

After earning a MS in health sciences from the University of California, Berkeley School of Public Health, Dr. Keet received a medical degree at the University of California, San Francisco School of Medicine. She completed a Pediatrics residency and an Allergy and Immunology fellowship at Johns Hopkins. She has a PhD in Genetic Epidemiology from the Johns Hopkins Bloomberg School of Public Health.



Edwin Kim, MD, MS University of North Carolina at Chapel Hill Dr. Edwin Kim is an associate professor and chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine. His research is on the development of novel therapeutics for food allergy with a particular focus on the use of immunotherapy for food allergy. He is the director of the UNC Food Allergy Initiative (UNC FAI) research group and he leads the UNC FAI within the NIH-sponsored Consortium for Food Allergy Research (CoFAR) and as a Discovery Center of Distinction within the FARE Clinical Network.



Mirelle Kleuskens, MSc Utrecht University Mirelle obtained her MSc degree in Animal Sciences in 2018 from Wageningen University, The Netherlands. During her studies, she developed a strong interest in human immunology, particularly allergy. After completing research projects in the Cell Biology and Immunology group of Wageningen University, and the Swiss Institute of Allergy and Asthma Research in Davos, Switzerland, she started her PhD trajectory in 2019 at Utrecht University, The Netherlands. Her current research focuses on the mechanisms and management of eosinophilic esophagitis.



Michael Kulis, PhD University of North Carolina at Chapel Hill Dr. Kulis is a biochemist whose work focuses on the development and mechanistic understanding of novel immunotherapy approaches for children with food allergies Using animal models and human samples, Dr. Kulis and his team have carried out projects to study humoral responses, particularly serum IgE, IgG, IgG4, and IgA; local IgA production in saliva; Treg enumeration using flow cytometry; Th2 cytokine secretion; and basophil activation assays to peanut and other allergens.

Currently, Dr. Kulis is exploring research questions in mouse models of food allergy, including the development of a novel therapeutic approach targeting inhibitory Siglecs (sialic-acid-binding immunoglobulin-like lectins) on B cells and mast cells/ basophils. His team has also recently developed a mouse model that reacts on oral peanut and walnut challenges, allowing for further research partnerships with the NIH and industry to develop a novel adjuvanted DNA vaccine and to test hypoallergenic peanuts. His future plans include studies focusing on the mechanisms and kinetics of basophil desensitization, Treg function and Th2 modulation mechanisms, and humoral responses. These studies have potential to identify biomarkers and reveal mechanisms of allergen immunotherapy, which will ultimately be useful to clinicians and their patients.



Dr. Lack is Professor of Pediatric Allergy at King's College London and Head of the Children's Allergy Clinical Academic Group at King's Health Partners Institute of Women and Children's Health at Evelina London Children's Hospital, Guy's & St. Thomas' NHS Foundation Trust. He studied medicine at Oxford University before training as a Pediatrician in New York and specialized in Allergy at National Jewish Health in Denver, Colorado. He was Professor of Pediatric Allergy and Immunology at Imperial College London where he worked for 12 years before moving to King's College London in 2006.

His research focuses on the prevalence of food allergies in children and the relationship between food allergies, eczema, and asthma. He works on novel immunomodulatory treatments for food allergies and on developing new strategies to prevent the development of allergies and asthma in children and adults.

Dr. Lack conducted the LEAP (Learning Early About Peanut allergy) study, which showed that early consumption of peanuts in atopic infants reduces the development of peanut allergy by >80%. In 2016-17 these findings were translated into changes in public health policy.



Jennifer Maloney, MD Regeneron Dr. Maloney graduated from Barnard College, where she was inducted into the Phi Beta Kappa honor society. She completed medical school at SUNY Stony Brook and was inducted in the Alpha Omega Alpha honor society. Medical school was followed by a pediatric residency and chief resident year at University Hospital, Stony Brook. Subsequently, she pursued an Allergy/Immunology fellowship at Mount Sinai School of Medicine. Jennifer remained on faculty within the Department of Pediatric Allergy at Mount Sinai following fellowship; the majority of her time was dedicated to research in the area of peanut allergy. Jennifer also co-developed the Eosinophilic Esophagitis program, the first multi-disciplinary clinical practice focused on the diagnosis and treatment of eosinophilic esophagitis in the NYC area, while at Mount Sinai.

Dr. Maloney transitioned to industry in 2007. She directed the clinical development programs, which included pediatric trials, for the grass, ragweed, and house dust mite allergy immunotherapy tablets. She conducted the Phase 3 trials for these products, which resulted in FDA approval for this new class of allergen immunotherapy. She joined ALK for 2 years to head the pharmacovigilance department for North America. Approximately 4 years ago, she joined Regeneron. She currently leads the global clinical dupilumab program as well as the anti-allergen monoclonal antibody programs.



Rasika Mathias, ScD

Dr. Mathias is a Professor of Medicine in the Division of Allergy and Clinical Immunology. She is a formally trained Genetic Epidemiologist with a particular emphasis on the genetics of human health and disease in the context of health disparities. She obtained her Bachelors of Science in Zoology at Stella Maris College in India and her ScM and ScD in Genetic Epidemiology at the Johns Hopkins Bloomberg School of Public Health. Dr. Mathias underwent her postdoctoral training at the National Human Genome Research Institute and has been faculty at Johns Hopkins since 2009. Her work spans asthma, atopic dermatitis and food allergy where she applies an integrative approach to bring together genetics, transcriptomics and epigenetics in understanding disease risk and predicting disease risk and response to intervention.



Kari Nadeau, MD, PhD Stanford University Dr. Nadeau is the Naddisy Foundation Endowed Professor of Medicine and Pediatrics, and Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. She is Section Chief in Asthma and Allergy in the Pulmonary, Allergy and Critical Care Division at Stanford. She is also the Sr. Director of Clinical Research for the Division of Hospital Medicine.

For more than 30 years, she has devoted herself to understanding how environmental and genetic factors affect the risk of developing allergies and asthma, and the molecular mechanisms underlying the diseases. As one of the nation's foremost experts in adult and pediatric allergy and asthma, her research is laying the groundwork for a variety of potential future therapies to prevent and cure allergies and asthma. She started four biotech companies in the Bay Area under Stanford patents and has worked in industry to shepherd two drugs through the FDA to approval.

Dr. Nadeau received her MD and PhD from Harvard Medical School. She completed a residency in pediatrics at Boston Children's Hospital and a clinical fellowship in asthma and immunology at Stanford and University of California, San Francisco. She has been a faculty member at Lucile Packard Children's Hospital Stanford since 2006.



Cathryn Nagler, PhD University of Chicago

inversity of officago

The inaugural Bunning Food Allergy Professor at the University of Chicago, Dr. Nagler is a world-leader in the microbiome and its relationship to food allergy and other intestinal disorders. She has identified a causal role for specific bacterial species in protection against food allergy. Her current work focuses on studying the molecular mechanisms by which bacterial metabolites interact with the host immune system. This research has informed the efforts of her start-up company ClostraBio to develop microbiome-modulating therapeutics for food allergy and inflammatory bowel disease.

Dr. Nagler graduated with honors from Barnard College, Columbia University. She obtained her PhD from NYU Grossman School of Medicine and did a postdoctoral fellowship at MIT. She was Associate Professor of Pediatrics (Immunology) at Harvard Medical School prior to joining the University of Chicago in 2009. Dr. Nagler serves in national and international leadership roles, many of which are related to publication and teaching, for the American Association of Immunologists, the Society for Mucosal Immunology and Federation of Clinical Immunology Societies. Dr. Nagler received the Distinguished Faculty Award for Leadership in Program Innovation from the University of Chicago in 2017. She was listed among Crain's Chicago Business Tech Top 50 Women in 2018 and Notable Women in HealthCare in 2019 for her work with her academic start-up company ClostraBio. Academic honors include the American Academy of Allergy, Asthma and Immunology (AAAAI) Foundation and Louis M. Mendelson Award Lectureship and the Siegel Lectureship at UCLA. She was elected as a Distinguished Fellow of the American Association of Immunologists (AAI) in 2020. She was recently named AAI Program Chair and, as such, is an ex officio member of the AAI Leadership Council.



Michiko Oyoshi, PhD, MSc

Massachusetts General Hospital

Dr. Oyoshi is an Assistant Professor of Pediatrics at Massachusetts General Hospital. Her laboratory focuses on two major areas: 1) the role of maternal factors transferred to babies through breast milk in inducing oral tolerance in children and 2) the mechanisms of eosinophil recruitment to the esophagus driven by allergic skin sensitization. Her aim is to promote the understanding of disease mechanisms, leading to the development of better prevention and treatment to combat the recent escalation in the prevalence of allergies.

Dr. Oyoshi obtained her doctorate in Medical Sciences from the Tokyo Medical and Dental University.



Bruce Robets, PhD

Bruce Roberts, PhD, is the Chief Research Strategy and Innovation Officer (RSIO) for FARE having joined in May 2020. In his RSIO role, he heads FARE's scientific and clinical research initiatives, leveraging his decades of experience in the biomedical industry.

Dr. Roberts joined FARE following his tenure at Vedanta Biosciences where he served as Chief Scientific Officer establishing therapeutic area strategy, streamlining drug discovery efforts and pushing forward multiple translational medicine collaborations in the areas of infectious diseases, cancer immunotherapy, inflammatory bowel disease and food allergy. Dr. Roberts has also held numerous research and development roles at major medical corporations including Sanofi and Genzyme.

Roberts is a regularly published author in the Journal of Immunology, the Journal of Neuroimmunology and other widely respected medical publications. A native of Canada, he is a graduate of the University of Ottawa where he earned a doctorate in Protein Chemistry and trained at the National Institute for Medical Research in Mill Hill, London.



Krishna Roskin, PhD Cincinnati Children's Hospital

Krishna Roskin, PhD, is an Assistant Professor of Pediatrics at the Cincinnati Children's Hospital Medical Center. As a bioinformatician and computational immunologist, Dr. Roskin pairs computational methods with immunological data to improve our understanding of human disease. Affiliated with both the Divisions of Biomedical Informatics and Immunobiology, his lab studies and catalogs changes in the immune receptor repertoire and links those changes to immunogen exposure, autoimmunity, immunodeficiency, and transplant status and allergy. Dr. Roskin received his doctorate in computer science from the University of California.

Medical Center



Alexandra Santos MD,

PhD King's College London Alexandra Santos, MD, PhD, is Professor of Pediatric Allergy at King's College London and Honorary Consultant in Pediatric Allergy at the Evelina London Children's Hospital.

Dr. Santos qualified in Medicine from the University of Coimbra and completed her PhD in Allergy and Immunology at King's College London, supervised by Professor Gideon Lack. Over the years, Alexandra has continued to combine clinical activity in Pediatric Allergy with clinical and laboratory translational research into food allergy.

The Santos Lab aims to improve the accuracy and safety of food allergy diagnosis and our understanding of the mechanisms of food allergy and oral tolerance in IgE-sensitized children to identify new targets for definitive treatment of food allergy.

Dr. Santos has received multiple prestigious awards from the Medical Research Council (MRC) and additional funding from the NIH, Food Allergy Research and Education (FARE), the Wellcome Trust, the European Commission, and Asthma UK as Principal Investigator of Asthma UK Centre in Allergic Mechanisms of Asthma.

She is the Chair of the Board of the Food Allergy Interest Group of European Academy of Allergy and Clinical Immunology (EAACI) and of the upcoming EAACI Food Allergy Guidelines.



Jonathan Spergel, MD, PhD Children's Hospital of Philadelphia

Dr. Spergel is a Professor of Pediatrics and holder of Stuart Starr Chair of Pediatrics at the Perelman School of Medicine at University of Pennsylvania, Chief of Allergy Section at Children's Hospital of Philadelphia and director of the Center for Pediatric Eosinophilic Disorders. He is the principal investigator for FARE's Data Coordinating Center and CHOP's FARE Clinical Network Center of Distinction.

His clinical and post-graduate research training in Allergy and Immunology was completed at Boston Children's Hospital and Harvard Medical School. Under the mentorship of Dr. Geha, Dr. Spergel developed a murine model of atopic march and atopic dermatitis. This model has been used for the last 20 years to study multiple atopic diseases including food allergy and eosinophilic esophagitis.

Dr. Spergel has worked from bench to bedside on numerous aspects of food allergy. He has identified genetic risk factors for eosinophilic esophagitis and Food allergy. Dr. Spergel identified any allergens, including food allergens, can sensitize skin in the mouse model.

He has held leadership in numerous academic societies including as a member of the Board of Directors for the American Academy of Allergy, Asthma and Immunology, and as Chair of the Medical Advisory Boards of the American Partnership for Eosinophilic Disorders and the International Food Protein Enterocolitis Syndrome Association.



Mimi Tang, MBBS, PhD University of Melbourne Professor Tang is a Pediatric immunologist allergist at Melbourne's Royal Children's Hospital, Group Leader of Allergy Immunology Research and Director of Food Allergy Translation at the Murdoch Children's Research Institute, and a Professor in the Department of Pediatrics at the University of Melbourne. She is also Change Chief Medical Officer to Chief Executive Officer at Prota Therapeutics and a Consultant Immunopathologist at Dorevitch Pathology.

Dr. Tang completed her medical degree at the University of Melbourne followed by a PhD in Immunology. She is internationally recognized in the field of allergy and immunology and has authored more than 350 peer-reviewed journal articles and book chapters. Her research program is focused on developing novel oral immunotherapies that induce remission of food allergies, with a lead product that harnesses the potent immune-modulating capacity of intestinal microbiota alongside allergen oral immunotherapy.



Alkis Togias, MD National Institute of Allergy and Infectious Diseases, National

Institutes of Health

Alkis Togias is the Chief of the Allergy, Asthma and Airway Biology Branch at the Division of Allergy, Immunology and Transplantation of the National Institute of Allergy and Infectious Diseases (NIAID), NIH. His responsibility is to supervise the stewardship of all NIAID-funded grants and programs, as well as the scientific research initiatives in allergic diseases, asthma and inflammatory upper airway conditions. This includes the NIAID-funded clinical networks (Childhood Asthma in Urban Settings [CAUSE], Consortium for Food Allergy Research [CoFAR], Atopic Dermatitis Research Network [ADRN], Asthma and Allergic Diseases Cooperative Research Centers [AADCRC], and the allergy projects of the Immune Tolerance Network [ITN], as well as investigatorinitiated clinical trials and investigator-initiated research project grants. Dr. Togias also co-directs the NIAID-funded Human Immunology Project Consortium (HIPC) and is a Project Scientist in the Airways Workgroup of the NIH-funded Environmental Influences on Child Health Outcomes (ECHO) initiative.

Dr. Togias earned his medical degree at the National and Kapodistrian University of Athens, Greece and received his post-doctoral research and clinical training in Medicine and then in Allergy and Clinical Immunology at the Johns Hopkins Hospital and University. He was on faculty at the Johns Hopkins University from 1989 to 2006, when he joined the NIH.



Paul Turner, PhD Imperial College London Dr. Turner is a Reader/Clinician Scientist and Honorary Consultant at Imperial, and Clinical Associate Professor at the University of Sydney, Australia. His research, funded by the Medical Research Council, European Commission and UK Food Standards Agency among others, focuses on the pathophysiology of severe allergic reactions to food. He is a member of the UK Food Standards Agency's Science Council, the United Nations Food & Agriculture Organization and World Health Organization Codex Expert Consultation on Risk Assessment of Food Allergens, and leads the European Academy of Allergy and Clinical Immunology Taskforce on Food Allergen Thresholds.

Dr. Turner is a graduate of Oxford University and the University of London. He trained in Pediatric Allergy and Immunology in Sydney and Great Ormond Street Hospital, London.



Carina Venter, PhD, RD University of Colorado School of Medicine Dr. Venter is an Associate Professor of Pediatrics, Section of Allergy/Immunology at the Children's Hospital Colorado and University of Colorado Denver. She is committed to helping children diagnosed with food allergies and has focused her research and clinical practice over the past 20 years on the prevention, diagnosis and management of food allergies and other allergic diseases. Her research examines how nutrition and other modifiable factors contribute to the development of allergic diseases and uses observational studies to identify risk factors such as epigenetic changes and the role of the microbiome.

Dr. Venter obtained her Bachelor of Science in dietetics from the University of the Free State, South Africa, followed by a postgraduate diploma in allergy and a PhD from the University of Southampton, United Kingdom. She is one of the founding members of the International Network for Diet and Nutrition in Allergy (INDANA) and was appointed to the expert panel of the National Institute of Allergy and Infectious Diseases (NIAID) to develop peanut allergy prevention guidelines.

Thank you to all our speakers!

For more information, visit:



Thank you to our sponsors:



